The Myasthenia Gravis Foundation of America (MGFA) is the only national volunteer health agency in the United States dedicated solely to the fight against myasthenia gravis. MGFA serves patients, their families and caregivers.
Myasthenia gravis (pronounced My-as-theen-ee-a Grav-us) comes from the Greek and Latin words meaning "grave muscular weakness." The most common form of MG is a chronic autoimmune neuromuscular disorder that is characterized by fluctuating weakness of the voluntary muscle groups. To learn more click here.
Participate in the “conversation” for Rare Disease Day, Feb. 29, 2016. The theme this year is the Patient Voice. For more information click here
Read more about Paula's struggle with insurance companies and how she dealt with them here.
If you are the parent of a child with MG, or you know one, MGFA is pleased to announce its new Parents’ Program and click on “More” at the bottom of the page to view Page 2 with more resources. Visit these new web pages for useful and informative resources and to access a webinar from Dr. Nancy Kuntz, a leading expert on MG in children, Northwestern Feinberg School of Medicine and Medical Director, Mazza Foundation Neuromuscular Disorders Program and MDA Clinic at Ann & Robert H. Lurie Children's Hospital of Chicago.
Are you a Parent of an MG Child? If so, you may be interested in MG Parents on Facebook. This is a Facebook page where parents can share their concerns, their triumphs, information and ideas. Take a look by searching MG Parents, or click here.
The MGFA is thrilled to announce a new awareness and fundraising initiative…Team ENDurance MG! This exciting program will empower all participants to raise funds for the MGFA and spread awareness about myasthenia gravis while training & participating in a “bucket list” activity such as a half or full marathon, triathlon or even an obstacle course race in mud! Learn more here!
The MGFA reached out to Dr. Jon Lindstrom, whose work, along with co-investigators, has focused on the possibility of a vaccine for MG as reported recently in the Journal of Immunology. Read more here.
We are now able to accept vehicle donations. For more information, click here.
Transformative Research Awards for Myasthenia Gravis and Related Neuromuscular Junction Disorders
Alexion Pharmaceuticals is conducting a clinical trial to determine if eculizumab is effective for the treatment of patients with refractory generalized Myasthenia Gravis (gMG). The enrollment for this study is complete. For information on MG and update on the study click here.
The Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) is currently looking for people with myasthenia gravis (MG) to be part of a research study. Read more here
Rituximab Study FAQs
Additional Rituximab Study Information
The American Society of Health System Pharmacists reported a shortage of Imuran. For more details, please click here.
The 2016 National Conference will be in Raleigh, NC May1st - May 3rd. We hope to see you there!
To make your hotel reservations, register for the conference and view the tentative agenda, click here.
To view videos from the 2015 National Conference click here.
There is no known cure for MG, but there are effective treatments that allow many-but not all-people with MG to lead full lives. Although the treatments will not cure MG, patients may have significant improvement in their muscle strength.